Skip to main content
OncoPrescribe
  • HOME
  • WHY US
  • ABOUT
  • SIGN IN
  • SIGN UP

Top Ad

oncoprescribe-top

Advertisement

ERLEADA® (Apalutamide)

February 16, 2018April 5, 2020 RR FDA Approvals
Prostate Cancer

The FDA on February 14, 2018 approved ERLEADA® for patients with Non-Metastatic Castration Resistant Prostate Cancer (NM-CRPC). ERLEADA® is a product of Janssen Biotech Inc.

Related Posts:

  • ERLEADA® (Apalutamide)
  • FDA Approves ERLEADA® for Non-Metastatic…

Post navigation

FDA Approves ZYTIGA® for High-Risk Metastatic Castration-Sensitive Prostate Cancer
Long Term Disease Free Survival Benefit with Adjuvant NERLYNX® in HER2-positive Breast Cancer

Bottom Ad

hem-onc-updates

Advertisement

Subscribe

Subscribe

Ad 1

oncoprescribe-ad

Advertisement

Ad 2

OncoPrescribe

Advertisement

Ad 3

OncoPrescribe.com-Ad

Advertisement

Ad 4

Immunization Schedule

Advertisement

  • HELP
  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
OncoPrescribe, LLC. All Rights Reserved